Physician profile
Amy Schell
NPI 1437265436
$2,204.68
in general payments reported to CMS, 2019-2025
15 companies · $70.29 in 2025
The $70.29 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.04 · 2021: $1,827 · 2022: $30.00 · 2023: $127 · 2024: $84.94 · 2025: $70.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244 · Education: $38.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.35 |
| Education | $38.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,720.95 | 2021-2024 | Enhertu |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Galvanize Therapeutics, INC | $113.12 | 2023 | Aliya System |
| Channel Medsystems, INC. | $38.15 | 2024 | |
| Iovance Biotherapeutics, INC. | $33.57 | 2025 | Amtagvi |
| Pfizer INC. | $32.74 | 2019-2024 | |
| Tosoh Bioscience, INC. | $25.00 | 2019 | |
| Gilead Sciences, INC. | $24.34 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $24.30 | 2025 | Injectafer |
| Array Biopharma INC | $22.49 | 2019 | |
| Novo Nordisk INC | $14.37 | 2023 | Wegovy |
| Merck Sharp & Dohme LLC | $5.65 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Schell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.